1. A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥65 Years) TREATMENT‐NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA. (12th June 2019) Authors: Wang, M.; Belada, D.; Cheah, C.; Chu, M.P.; Dreyling, M.; Flinn, I.; Fogliatto, L.; Goy, A.; Inwards, D.; Jurczak, W.; Mayer, J.; Re, F.; Robak, T.; Spurgeon, S.; Yoon, S.S.; Zinzani, P.L.; Yin, M.; Chen, T.; Kahl, B. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 554 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗